DSIP: Research Overview

The short version

DSIP, short for Delta Sleep-Inducing Peptide, is a small endogenous peptide — meaning it was first found occurring naturally in the body, not synthesized as a drug candidate. Researchers isolated it in 1977 from the cerebral venous blood of rabbits during electrically induced sleep, and named it for its ability to enhance slow, "delta-wave" brain activity — the deep, restorative stage of sleep — when infused directly into the brain.

Despite more than forty years of study, no specific DSIP receptor, gene, or precursor protein has ever been conclusively identified. A 2006 review in the Journal of Neurochemistry summarized DSIP as a "still unresolved riddle," and described its core sleep-promoting evidence as "extremely poorly documented and still weak" ^[12]. DSIP is not approved as a drug anywhere; in the US it circulates only as a research chemical.

DSIP is the lead compound on this desk. Some of its most-cited studies used intranasal administration, which is why it belongs on a nose-to-brain research desk even though its mechanism remains genuinely unsettled.

What it is

DSIP is a linear nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (molecular formula C35H48N10O15). A naturally occurring phosphorylated form, DSIP-P, is also described in the literature and is reported as more potent in some assays. Its International Nonproprietary Name, Emideltide, exists on paper, but no Emideltide product has ever been approved or marketed by any regulator.

How it works

DSIP's mechanism is the least resolved of the three peptides on this desk. No DSIP receptor, gene, or precursor has been isolated despite decades of research. What is known: DSIP crosses the blood-brain barrier via a saturable transporter that is competitively inhibited by L-tryptophan, its reported growth-hormone effect in rodents runs through a pimozide-sensitive dopaminergic relay, and older withdrawal-syndrome studies proposed an interaction with the endogenous opioid system. Its proposed roles in sleep, the stress (HPA) axis, and neuroendocrine secretion are, in the words of the 2006 review, "plausible but incompletely validated" ^[12].

What the research shows

Blood-brain-barrier-engineered fusion peptide (2024). A DSIP fusion peptide engineered to cross the blood-brain barrier reduced average daily wakefulness from roughly 720 to 500 minutes (about 31%) in PCPA-induced insomnia mice, restored melatonin, serotonin, and dopamine levels, produced anxiolytic and antidepressant-like effects, and increased hippocampal neuron density — outperforming unmodified native DSIP in the same model ^[11].

The 2006 review. A comprehensive review concluded the link between DSIP and sleep was never fully characterized: the sleep-promotion hypothesis is "extremely poorly documented and still weak," no DSIP gene, protein, or receptor has been isolated, and artificial DSIP analogs — not native DSIP — showed the clearest sleep-promoting effects in the literature it surveyed ^[12].

Lifespan and tumor data in mice. Monthly courses of the DSIP-containing preparation Deltaran in female SHR mice increased maximum lifespan by 24.1%, extended the lifespan of the longest-lived 10% of survivors by 17.1%, reduced total spontaneous tumor incidence 2.6-fold, and reduced bone-marrow chromosome aberrations by 22.6% ^[13].

Human ACTH data. Intravenous DSIP in men produced a significant reduction in plasma ACTH-like immunoreactivity for at least three hours, while plasma cortisol was unaffected and followed its normal diurnal decline ^[14].

Human insomnia trial. Acute intravenous synthetic DSIP improved disturbed sleep in six middle-aged chronic insomniacs — longer duration, fewer interruptions, slightly more REM sleep, and no daytime sedation — with the sleep-promoting effect emerging in the second hour after injection ^[15].

Original characterization. DSIP was first isolated and characterized in 1977 as the nonapeptide above; infused intraventricularly in rabbits, it produced significant and specific enhancement of delta and spindle EEG activity, establishing both the sequence and the effect the peptide is named for ^[16].

Intranasal dosing after stroke. Intranasal DSIP given around a focal stroke in adult rats significantly improved motor-function recovery by day seven, while infarct volume (20.9% versus 24.1% in vehicle) was not statistically different — a pattern the study's authors interpreted as a neuroprotective, functional-recovery effect rather than one that limits the size of the lesion itself ^[17].

Reported effects, cautions & safety

Reported benefits (anecdotal, not clinical evidence): People who respond describe an easier transition into sleep, a quieter mind, and — among those who notice a difference — deeper, more restorative-feeling sleep with fewer night wakings. A frequently repeated theme is waking without the heavy grogginess associated with melatonin or prescription sleep aids. Vivid or more memorable dreaming is one of the most commonly reported effects, generally described as pleasant or neutral. Some describe a calmer, lower-stress daytime feeling as a secondary effect.

Reported adverse effects (anecdotal, not clinical evidence): Headache is the most commonly reported side effect, usually described as mild and transient, and tied by many users to using too much. A notable minority describe unpredictable or delayed timing — sedation arriving the next day rather than that night — and a smaller minority report next-day grogginess, mild nausea, or dizziness. Most importantly: a large share of people report no noticeable effect at all, with one commonly repeated estimate putting DSIP's response rate at roughly half of those who try it.

Cited cautions from the literature:

• Unregulated sourcing. DSIP is not an approved drug anywhere; despite an assigned INN (Emideltide), no Emideltide product has been marketed. Material sold online is research-grade, with no pharmaceutical quality, purity, or sterility standard.
• Genuinely unresolved mechanism. No DSIP receptor, gene, or precursor has been identified after more than forty years of study ^[12]; when the basic mechanism is unknown, there is no sound basis for predicting drug interactions, and the literature separately reports an unusual non-monotonic (parabolic) dose-response, meaning more is not reliably stronger.
• Thin human safety data. Human study of DSIP is limited to small, mostly 1980s pilot trials and short neuroendocrine experiments ^[14][15]; there is no large or long-duration controlled human safety study, and its measured half-life in animals is only minutes.
• Self-treating a sleep problem can mask a treatable condition. Persistent trouble sleeping can signal sleep apnea, a circadian disorder, depression, or a thyroid problem; DSIP has not been shown in modern controlled trials to treat any diagnosed sleep disorder, and even the early human work described its effect as modest ^[15].
• Combination with sedatives is untested. Stacking an agent with an unresolved central-nervous-system mechanism on top of sleep medications, benzodiazepines, or alcohol has never been formally studied.
• Inconsistent, frequently absent benefit. Both community reports and the formal literature agree that DSIP's effects are unreliable; approaching it with an expectation of reliable sleep improvement is not supported by the evidence ^[12][15].

Where it fits in Cognitive & Nootropic research

DSIP is the lead compound on this desk, and its intranasal stroke-recovery study ^[17] is one of the three data points — alongside Semax's intranasal neurotrophin work ^[3] and Selank's intranasal BDNF study ^[9] — behind this site's nose-to-brain framing. It is also, by a wide margin, the least mechanistically resolved of the three: no receptor has ever been identified for it, a gap that Semax and Selank do not share to the same degree. Read the comparison page to see how the three peptides' evidence bases, mechanisms, and cautions line up.